Filters: Keyword is Opioid-Related Disorders [Clear All Filters]
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"Illicit use of opioids: is OxyContin a "gateway drug"?" The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 16, no. 3 (2007): 166-73. Abstract
"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
"Initial strategies for integrating buprenorphine into HIV care settings in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S191-6. Abstract
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Integrating buprenorphine treatment into office-based practice: a qualitative study." Journal of general internal medicine 24, no. 2 (2009): 218-25. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
"Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
"Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance." Antimicrobial agents and chemotherapy 57, no. 12 (2013): 6154-7. Abstract
"Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction." AIDS (London, England) 19, no. 15 (2005): 1635-41. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"Lessons from Tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment." The International journal on drug policy 25, no. 1 (2014): 22-5. Abstract
"Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia." Drug and alcohol dependence 124, no. 1-2 (2012): 177-80. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence." The American journal of psychiatry 162, no. 2 (2005): 340-9. Abstract
"Models for integrating buprenorphine therapy into the primary HIV care setting." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 42, no. 5 (2006): 716-21. Abstract
"Narrative review: buprenorphine for opioid-dependent patients in office practice." Annals of internal medicine 148, no. 9 (2008): 662-70. Abstract
"New federal initiatives to enhance the medical treatment of opioid dependence." Annals of internal medicine 137, no. 8 (2002): 688-92. Abstract
"Next steps for Ukraine abolition of HIV registries, implementation of routine human immunodeficiency virus testing and expansion of services." Addiction (Abingdon, England) 105, no. 3 (2010): 569-70.
"Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates." Drug and alcohol dependence 94, no. 1-3 (2008): 38-47. Abstract
"Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates." Archives of internal medicine 171, no. 11 (2011): 1034-6.
"Nonmedical use of prescription opioids and pain in veterans with and without HIV." Pain 152, no. 5 (2011): 1133-8. Abstract
"Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?" CNS drugs 22, no. 2 (2008): 99-111. Abstract
"Opioid dependence: rationale for and efficacy of existing and new treatments." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S173-7. Abstract
"Opioid use disorder in the United States: insurance status and treatment access." Drug and alcohol dependence 94, no. 1-3 (2008): 207-13. Abstract
"Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S91-7. Abstract
"Opioids, chronic pain, and addiction in primary care." The journal of pain : official journal of the American Pain Society 11, no. 12 (2010): 1442-50. Abstract
"Oral substitution treatment of injecting opioid users for prevention of HIV infection." Cochrane database of systematic reviews (Online), no. 8 (2011): CD004145. Abstract
"Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 18, no. 2 (2009): 117-21. Abstract
"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract
"Patient satisfaction with primary care office-based buprenorphine/naloxone treatment." Journal of general internal medicine 22, no. 2 (2007): 242-5. Abstract
"Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence." The American journal of drug and alcohol abuse 37, no. 1 (2011): 1-11. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 11, no. 1 (2002): 66-74. Abstract
"Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence." Journal of substance abuse treatment 32, no. 4 (2007): 399-409. Abstract
"A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners." Journal of opioid management 4, no. 2 (2008): 81-6. Abstract
"The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S178-83. Abstract
"The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?" Drug and alcohol dependence 79, no. 1 (2005): 113-6. Abstract
"A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients." Journal of addictive diseases 22, no. 2 (2003): 49-61. Abstract
"Prevalence and experience of chronic pain in suburban drug injectors." Drug and alcohol dependence 151 (2015): 92-100. Abstract
"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients." Journal of general internal medicine 22, no. 4 (2007): 527-30. Abstract
"Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 13 Suppl 1 (2004): S67-78. Abstract
"The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 37, no. 4 (2003): 476-82. Abstract
"Provider satisfaction with office-based treatment of opioid dependence: a systematic review." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 26, no. 1 (2005): 15-22. Abstract
"Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients." The Journal of clinical psychiatry 70, no. 9 (2009): 1213-8. Abstract
